Synthetic Medicinal Chemistry (CHEM3115)
UNIT OF STUDY
The development of new pharmaceuticals fundamentally relies on the ability to design and synthesize new compounds. Synthesis is an enabling discipline for medicinal chemistry - without it, the development of new drugs cannot progress from design to implementation, and ultimately to a cure. This unit will tackle important factors in drug design, and will highlight the current arsenal of methods used in the discovery of new drugs, including rational drug design, high throughput screening and combinatorial chemistry. We will develop a logical approach to planning a synthesis of a particular target structure. The synthesis and chemistry of heterocycles, which comprise some 40% of all known organic compounds and are particularly common in pharmaceuticals, will be outlined. Examples will include important ring systems present in biological systems, such as pyrimidines and purines (DNA and RNA), imidazole and thiazole (amino acids and vitamins) and porphyrins (natural colouring substances and oxygen carrying component of blood). Throughout the course, the utility of synthesis in medicinal chemistry will be illustrated with case studies such as anti-influenza (Relenza), anaesthetic (benzocaine), anti-inflammatory (Vioxx), antihypertensive (pinacidil) and cholesterol-lowering (Lovastatin) drugs.
Further unit of study information
Two 1-hour lectures and one 4-hour practical per week.
One 2-hour exam, written assignments, prac reports (100%)
Faculty/department permission required?
Unit of study rules
Prerequisites and assumed knowledge
(CHEM2401 or CHEM2911 or CHEM2915) and (CHEM2402 or CHEM2912 or CHEM2916)
Study this unit outside a degree
If you wish to undertake one or more units of study (subjects) for your own interest but not towards a degree, you may enrol in single units as a non-award student.
If you are from another Australian tertiary institution you may be permitted to underake cross-institutional study in one or more units of study at the University of Sydney.